AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04058002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiprofessional treatment and Educational Program Associated (EPA+C) with supplementation of creatine only.
Description: 17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of placebo.
Study NCT02125071 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Blood Sample Collection before and after the administration of I.V. Hepabig Inj. on LT day(0 day); 1 day after; 1, 4, 12 and 24 weeks after LT.
Study NCT03876106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUT014
Description: Topical
Study NCT00869947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered ankle-foot prosthesis
Description: The powered ankle-foot prosthesis is comprised of a series-elastic actuator (SEA) and an elastic leaf spring. This technology has been previously developed for robotic and human rehabilitation applications. The SEA allows for precise force control of the ankle joint, thus mimicking the spring-like behavior of the human ankle, as well as providing adequate energy for forward progression of the body. From the early stance period to the mid-stance period of walking, the SEA will be controlled so that the ankle joint behaves like a spring. During the late stance period, the SEA will be employed to power the forward movement of the body. The elastic leaf spring will provide shock absorption during foot strike, energy storage during early stance, and energy return during late stance.
Study NCT00869947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No device
Study NCT01210651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha Yoga Practice Group
Description: The hatha yoga intervention was a sequence of classical yoga practices, comprised of breathing techniques, mindful body postures, and a final deep relaxation pose. The same sequence was used in all sessions. Yoga practices were broken down into component elements and taught progressively to each student in accordance with his or her ability. Participants were encouraged to remain within their range of motion or comfort. Accommodations were made for those with limitations in tolerance or flexibility for any exercise. Blocks, bolsters and other props were used to support participants in learning and holding yoga poses safely, particularly during back-bends or inverted poses. The intervention was delivered by a licensed, registered nurse, who was also a registered yoga teacher.
Study NCT01210651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Education Group
Description: The educational seminars taught to participants covered the history and philosophy of the main branches of yoga. Documentary films were used during the seminars to enhance lectures, and interactive dialogue was encouraged between instructor and participants. Seminars were designed to control for non-specific mood benefits of study participation, such as attention from instructors, peer interaction, time spent away from routine activities, and anticipation/interest related to mastering novel yoga-related information. Since participants would join the attention control group on a rolling basis, seminars were designed to function as stand-alone educational modules, rather than requiring presentation in a specific sequence. The instructor for the seminars was a registered yoga teacher.
Study NCT00895726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD209
Description: Oral tablets twice per day for 56 days
Study NCT01498315 — intervention group
Intervention type: OTHER
Intervention: Ultrasound examination
Description: Ultrasound examination following hysterectomy
Study NCT01690468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triciribine
Description: Triciribine (15, 25, 30, 35, or 45 mg/m\^2) on days 1, 8, 15 every 21 days. To be given as a 60 minute IV infusion.
Study NCT01690468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered on day 1 every 21 days, as a 30 minute IV infusion after completion of TCN.
Study NCT02437357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metacognitive Training
Description: 8 group sessions á 60 min
Study NCT02437357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positivity Training
Description: 8 group sessions á 60 min
Study NCT04058834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434
Description: Healthy volunteers and patients will receive one injection s.c. (subcutaneously, under the skin)
Study NCT04058834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0385-0434)
Description: Healthy volunteers will receive one injection s.c.
Study NCT02478645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron 0.3
Description: The ramosetron 0.3 group receives ramosetron 0.3 mg at the end of surgery.
Study NCT02478645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramosetron 0.45
Description: The ramosetron 0.45 group receives ramosetron 0.45 mg at the end of surgery.
Study NCT02478645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramosetron 0.6
Description: The ramosetron 0.6 group receives ramosetron 0.6 mg at the end of surgery.
Study NCT02469883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinotecean
Study NCT02397447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momordica charantia
Description: Momordica Charantia: 2000 mg per day for three months
Study NCT02397447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 2000 mg per day for three months
Study NCT04099485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Best Practice Advisory
Description: The AFDST is a decision support tool that is embedded in our electronic health record system. Currently, this is a passive tool that requires the clinician to launch the tool if an analysis is desired. The experimental arm of this study will add a best practice advisory (BPA) that will trigger when a clinician is in the medical record of an AF patient who might gain substantial benefit (survival and quality of life) if treatment were changed from the current anticoagulation plan, which might be no anticoagulant therapy.
Study NCT00698347 — intervention group
Intervention type: DEVICE
Intervention: M2a-Magnum™ Hip System
Study NCT00616824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dermamatrix to cover lateral aspect of tissue expander
Description: Dermamatrix used to cover lateral aspect of breast tissue expander after mastectomy
Study NCT00616824 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior to cover lateral aspect of tissue expander
Description: Traditional use of serratus anterior for coverage of lateral aspect of tissue expander
Study NCT04360785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Patients randomized in this arm will have one subcutaneous injection of methotrexate 15min before and one 24h after their first injection of adalimumab prescribed as usual
Study NCT01144390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy, one session per week and psycho-education lecture in group once per month
Study NCT01144390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone maintenance treatment
Description: methadone maintenance treatment
Study NCT01144390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone maintenance treatment
Description: methadone maintenance treatment
Study NCT03755973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFA
Description: Long-acting exogenous ovarian stimulation
Study NCT02840227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia with opioid analgesia
Description: General anesthesia with routine drugs and intravenous patient controlled opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
Study NCT02840227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined general/epidural anesthesia
Description: Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
Study NCT04519762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycophos (Sodium Glycerophosphate)
Description: Management of hypophosphatemia via Glycophos Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
Study NCT04519762 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Antibiotics
Description: Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
Study NCT04519762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
Study NCT04519762 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Inotropes
Description: Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
Study NCT04519762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inotropes
Description: Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
Study NCT03092791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)
Description: sIPV intramuscular injection
Study NCT03755973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFSH
Description: Daily rFSH
Study NCT03755973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH
Description: Daily rFSH
Study NCT03755973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fixed daily rFSH dosing protocol of 200-300 IU
Description: The dose of daily rFSH is fixed at 200 or 300 IU
Study NCT03755973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed daily rFSH dosing protocol of 200-300 IU
Description: The dose of daily rFSH is fixed at 200 or 300 IU
Study NCT03755973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Step-down daily rFSH dose
Description: The dose of daily rFSH is progressively reduced
Study NCT04287283 — intervention group
Intervention type: OTHER
Intervention: Hyperbaric Oxygen
Description: 40-60 daily hyperbaric sessions, 5 days per week. Each session consists of 90 minutes exposure to 100% oxygen at 1.5-2 ATA.
Study NCT02825251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Injected s.c. /subcutaneously (under the skin)
Study NCT02825251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected s.c. /subcutaneously (under the skin)
Study NCT02080403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 mg Chlorhexidine gluconate chip
Description: Subgingival debridement will be carried out for each one of the target implant. Upon completion of the debridement a PerioChip® will be inserted in each one of the target implant.
Study NCT02089139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Discogel
Description: DiscoGel is a sterile viscous solution containing ethyl alcohol, cellulose derivative product and tungsten (radio-opaque element)
Study NCT02089139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: Conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to:~* medications (analgesics, NSAIDs, muscle relaxants),~* physical therapy,~* manual techniques,~* transcutaneous electrical nerve stimulation (TENS),~* blocks
Study NCT02089139 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: Conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to:~* medications (analgesics, NSAIDs, muscle relaxants),~* physical therapy,~* manual techniques,~* transcutaneous electrical nerve stimulation (TENS),~* blocks
Study NCT02987647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hidrafemme
Description: The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
Study NCT02987647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vagidrat
Description: The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
Study NCT02987647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lubrinat
Description: The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
Study NCT02987647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antrofi
Description: The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
Study NCT02812992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Study NCT02812992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT02812992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Study NCT03795168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial vibrating system
Description: The transcranial vibrating system (TCVS) will be worn by participants performing vestibular physical therapy (PT) exercises. The TCVS vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises. The TCVS will be set at an optimal vibration frequency as determined in a previous study.
Study NCT03795168 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial vibrating system
Description: The transcranial vibrating system (TCVS) will be worn by participants performing vestibular physical therapy (PT) exercises. The TCVS vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises. The TCVS will be set at an optimal vibration frequency as determined in a previous study.
Study NCT03795168 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial vibrating system sham
Description: A transcranial vibrating system (TCVS) sham set at an irrelevant vibrating frequency will be worn by participants performing vestibular physical therapy (PT) exercises in arm 2. The TCVS sham vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS sham will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises.
Study NCT02861196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy, Radical cystectomy
Description: Postoperative Intensity modulated radiation therapy(IMRT) will be applied to effective team.Radical cystectomy will be applied to ineffective team.
Study NCT04361383 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: the patient will receive general anesthesia
Study NCT04361383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quadratus lumborum block type 3
Description: patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
Study NCT03092791 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference IPV
Description: Reference IPV intramuscular injection
Study NCT03092791 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: sIPV Placebo
Description: sIPV placebo-matching intramuscular injection
Study NCT03132974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sogyeonghwalhyeol-tang granule
Description: Sogyeonghwalhyeol-tang herbal extract granule
Study NCT03132974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sogyeonghwalhyeol-tang granule with manipulation procedure
Description: Sogyeonghwalhyeol-tang herbal extract granule with manipulation procedure
Study NCT04361383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block
Description: patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
Study NCT03484494 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Low Field Magnetic Stimulation
Description: Low Field Magnetic Stimulation is an application of a series of electromagnetic pulses to the brain through a small cylinder that the subject places the top of their head inside.
Study NCT02382562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation Intervention
Description: Clinical psychologists (investigators) will instruct the participant in ways to become more active in life, particularly with regards to activities that the participant finds pleasurable and meaningful. The intervention will take one hour to complete. Following the intervention, the participant will receive brief, weekly text or email reminders for the next 4 weeks (total of 4) to engage in pleasurable and meaningful activities during the week.
Study NCT06119347 — intervention group
Intervention type: DRUG
Intervention: AntiVEGF
Description: anti-vascular endothelial growth factor monoclonal antibody drug includes bevacizumab;
Study NCT06119347 — intervention group
Intervention type: DRUG
Intervention: ICIs
Description: immune checkpoint inhibitors include Pembrolizumab, Sintilimab, toripalimab, Camrelizumab, Tislelizumab.
Study NCT03587337 — intervention group
Intervention type: OTHER
Intervention: POEM
Description: Pt. are going to submit a POEM procedure.
Study NCT01473745 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional alar base cinch
Description: The conventional suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
Study NCT01473745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified alar base cinch
Description: The modified suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
Study NCT00404885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO BID
Study NCT00404885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.2 mg/kg, twice a day (BID)
Study NCT00404885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.4 mg/kg, twice a day (BID)
Study NCT00404885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.6 mg/kg, twice a day (BID)
Study NCT02414009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die refracted in two daily doses from day 1 to day 14 every 28 days
Study NCT02414009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients in Arm A will receive temozolomide 150 mg/mq/die refracted in two daily doses starting on day 10 to 14 every 28 days.
Study NCT02414009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
Study NCT02414009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
Study NCT02414009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.